A novel phosphodiesterase 4 inhibitor template

Abstract

Three patents claim 2-aryl-5,7-dialkyl-imidazo[5,1-f][1,2,4]-triazin-4(3H)-one derivatives as selective phosphodiesterase 4 (PDE4) inhibitors useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory diseases. The compounds are closely related to a series of sulfonamide derivatives of imidazotriazinones that inhibit PDE5 and/or enhance the activity of cGMP and a series of 2-aryl-4-aryloxyimidazotriazine derivatives useful as PDE10A inhibitors. The claimed compounds probably include Bayer’s second clinical development candidate BAY 61-9987.

• asthma
• BAY 61-9987
• chronic obstructive pulmonary disease (COPD)
• inflammation
• neutrophil
• phosphodiesterase 4 (PDE4) inhibitor
• PDE5 inhibitor
• PDE10A inhibitor
• vardenafil